Triple-targeted CD19/CD20/CD22 cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Triple-targeted CD19/CD20/CD22 cell therapy, covering 2025-06-03 to 2025-06-03. Get the full timeline:
Most recent: Clinical Trial Update: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]